GAINESVILLE – Cyclo Therapeutics, Inc. (NASDAQ:CYTH), a clinical-stage biotechnology company, has unveiled the granting of a U.S. patent for their offering, Trappsol® Cyclo™, targeted at addressing early onset Alzheimer’s disease. The patent, awarded by the United States Patent and Trademark Office, is titled “Approaches for Managing Alzheimer’s Disease” and emphasizes the company’s ongoing initiatives to develop therapeutic options for this ailment.
The new patent emerges as a significant augmentation to Cyclo Therapeutics’ collection, particularly as the company is presently undertaking a Phase 2b clinical trial with Trappsol® Cyclo™.
This study revolves around early Alzheimer’s disease, following encouraging results from an Expanded Access program. The patented product has already been assigned as an orphan drug in the United States and Europe, and it is also undergoing trials in four formal clinical studies for Niemann-Pick Disease Type C1, a rare genetic disorder.
N. Scott Fine, CEO of Cyclo Therapeutics, conveyed the company’s dedication to catering to the unmet medical requirements of patients and families encountering early onset Alzheimer’s disease. The firm harbors belief in the potential of Trappsol® Cyclo™ to meet these necessities and continues to bolster its patent estate encircling the product.
The organization has explicitly stated that this press release contains forward-looking declarations, which mirror existing anticipations about future outcomes and opportunities. Nonetheless, these declarations are not assurances of future performance and remain subject to risks, uncertainties, and other aspects that could sway the company’s actual results.
Cyclo Therapeutics has delineated its mission to devise life-changing medications for patients grappling with ailments, and the recent patent grant signifies a step ahead in its pursuits. As the company progresses with its clinical examinations and product development, it remains to be discerned how this patent will contribute to the treatment realm for Alzheimer’s disease.
This write-up is grounded on a press release declaration from Cyclo Therapeutics, Inc.
This article was produced with the backing of AI and assessed by an editor. For further details see our T&C.
